Chronic myeloproliferative neoplasms (MPN) are stem cell disorders driven by mutations in
JAK2, CALR, or MPL genes and characterized by myeloid proliferation and increased blood …

Following their discovery at the end of the 20th century, extracellular vesicles (EVs) ranging
from 50-1,000 nm have proven to be paramount in the progression of many cancers …

Platelets play a critical role in hemostasis and thrombus formation. Platelets are small,
anucleate, and short-lived blood cells that are produced by the large, polyploid, and …

Myeloproliferative neoplasms (MPNs) are rare, clonal disorders of the hematopoietic stem
cell in which an uncontrolled proliferation of terminally differentiated myeloid cells is noted …

Ruxolitinib (RUX), the first JAK1/JAK2 inhibitor approved for myelofibrosis (MF) therapy, has
recently been associated with the occurrence of second primary malignancies (SPMs) …

Simple Summary Extracellular vesicles (EVs) are released by the majority of cell types and
can be isolated from both cell cultures and body fluids. They are involved in cell-to-cell …

Myelofibrosis (MF) is characterized by chronic inflammation and hyper-activation of the JAK-
STAT pathway. Infections are one of the main causes of morbidity/mortality. Therapy with …

Platelet‐derived extracellular vesicles (PEVs) were originally studied for their potential as
regulators of coagulation, a function redundant with that of their parent cells. However, as …

Myeloid neoplasms arise from malignant primitive cells, which exhibit growth advantage
within the bone marrow microenvironment (BMM). The interaction between these malignant …

Myeloproliferative Neoplasms (MPN) are acquired clonal disorders of the hematopoietic
stem cells and include Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis …